Cargando…
The Structural Basis of Mycobacterium tuberculosis RpoB Drug-Resistant Clinical Mutations on Rifampicin Drug Binding
Tuberculosis (TB), caused by the Mycobacterium tuberculosis infection, continues to be a leading cause of morbidity and mortality in developing countries. Resistance to the first-line anti-TB drugs, isoniazid (INH) and rifampicin (RIF), is a major drawback to effective TB treatment. Genetic mutation...
Autores principales: | Amusengeri, Arnold, Khan, Asifullah, Tastan Bishop, Özlem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8839920/ https://www.ncbi.nlm.nih.gov/pubmed/35164151 http://dx.doi.org/10.3390/molecules27030885 |
Ejemplares similares
-
Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed rpoB Mutations and Discordant Susceptibility Phenotypes
por: Wang, Wei, et al.
Publicado: (2022) -
HIV Coinfection Is Associated with Low-Fitness rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis
por: Loiseau, Chloé, et al.
Publicado: (2020) -
A Glutamine Insertion at Codon 432 of RpoB Confers Rifampicin Resistance in Mycobacterium tuberculosis
por: Lai, Li-Yin, et al.
Publicado: (2020) -
rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis
por: Li, Ma-chao, et al.
Publicado: (2021) -
Detection of Mycobacterium tuberculosis Rifampicin Resistance Conferred by Borderline rpoB Mutations: Xpert MTB/RIF is Superior to Phenotypic Drug Susceptibility Testing
por: Xia, Hui, et al.
Publicado: (2022)